ethris – Enabling Therapies

Ethris develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options.

>>>

IMAGINE...
GENE THERAPY WITHOUT GENES

NEWS

July 20, 2016
Ethris Adds Three New Members to its Board of Directors

Leon Chen (OrbiMed), Thomas Chalberg (Oncorus, Inc.) and Justin Duckworth (HS LifeSciences) Join Ethris’ Board to Support Next Stage of Company’s Development

>>>
March 22, 2016
Ethris’ modified mRNA induces Bone Regeneration in Different Settings

Ethris publishes Preclinical Data on Musculoskeletal Regeneration in “Biomaterials” Journal

>>>

GET IN TOUCH

ethris GmbH
Semmelweisstr. 3
82152 Planegg
Deutschland

T +49 89 89 55 788 0
F +49 89 89 55 788 18

info@ethris.com

OUR TECHNOLOGY

Ethris explores the code of life for enabling patients’ bodies to make their own protein drugs. The proprietary SNIM®RNA platform and tailor-made delivery systems for systemic, local, oral and aerosol administration reduce gene therapy without genes to practice of medical need. SNIM®RNA “Transcript Therapies” are unprecedented treatment options for numerous diseases.

>>>